NCT06395090
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06395090
Title A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
Acronym MK-9999-01B/LIGHTBEAM-U01
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: adult | child
Covered Countries USA

Facility Status City State Zip Country Details
Yale-New Haven Hospital ( Site 2012) New Haven Connecticut 06510 United States Details
University of Iowa-Holden Comprehensive Cancer Center ( Site 2017) Iowa City Iowa 52242 United States Details
Children's Mercy Hospital ( Site 2024) Kansas City Missouri 64108 United States Details
Rutgers Cancer Institute of New Jersey ( Site 2008) New Brunswick New Jersey 08903 United States Details
New York Medical College ( Site 2023) Valhalla New York 10595 United States Details
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2003) Fargo North Dakota 58122 United States Details
Children's Hospital of Philadelphia (CHOP) ( Site 2021) Philadelphia Pennsylvania 19104 United States Details
Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 2015) Sioux Falls South Dakota 57105 United States Details
Intermountain - Primary Children's Hospital ( Site 2014) Salt Lake City Utah 84113 United States Details
Seoul National University Hospital-Pediatrics ( Site 2972) Seoul 03080 South Korea Details
Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 2973) Seoul 05505 South Korea Details
National Taiwan University Hospital ( Site 2983) Taipei 10002 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field